Poxel
May 26, 2020
Algernon’s NP-120; FDA nod to 4DMedical tool; SaNOtize’s NORSTM trial; Pole’s capital increase
Algernon Pharmaceuticals has announced the submission of an Investigational New Drug (IND) application of its drug, NP-120 for COVID-19. The company has submitted the IND with the US FDA for its planned multinational Phase 2b/3 study of its repurposed drug NP-120 (Ifenprodil) for the treatment of patients ...
Read More...
Feb 14, 2018
Business Cocktail
Roivant expanding its horizon into metabolic diseases segment with USD 650 million diabetes pact with Poxel Roivant Sciences has recently signed a USD 650 million deal to acquire near-global rights to Poxel pharma’s phase 3-ready Type 2 diabetes drug (imeglimin). It’s been a while since Poxel was waiting f...
Read More...
-Agonist.png "Toll-like Receptors Agonist")
